tiprankstipranks
Trending News
More News >

Vertex Pharmaceuticals announces MHRA approval of ALYFTREK for CF

Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator modulator treatment for people living with cystic fibrosis ages 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue